A novel PAAoptosis-inducing ERRα-targeting compound for combating hematopoietic and solid cancers - PubMed
6 hours ago
- #Cancer therapy
- #ERRα-targeting
- #PAAoptosis
- PAMT-001 is a novel compound targeting ERRα, showing strong anticancer effects in both hematological and solid tumors.
- It induces a combined cell death mechanism termed 'PAAoptosis,' involving pyroptosis, autophagic cell death, and apoptosis.
- Mechanistically, PAMT-001 disrupts mitochondrial function, increases reactive oxygen species, causes ER stress, and triggers gasdermin E-mediated pyroptosis.
- The compound has potential for precision medicine, especially in chemotherapy-resistant and NPM1-mutated acute myeloid leukemia.
- While less active than XCT-790 in ERRα binding, PAMT-001 demonstrates superior anticancer efficacy in preclinical models.